 Masanori Hayashi
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 8 | 2025 | 96 | 3.290 |
Why?
| | Bone Neoplasms | 10 | 2025 | 248 | 2.190 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1272 | 1.140 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 59 | 0.930 |
Why?
| | Clonal Evolution | 1 | 2025 | 45 | 0.910 |
Why?
| | Wnt Signaling Pathway | 2 | 2024 | 192 | 0.870 |
Why?
| | Hindlimb | 2 | 2024 | 128 | 0.860 |
Why?
| | Hydrogen | 1 | 2024 | 70 | 0.850 |
Why?
| | Cadherins | 1 | 2024 | 205 | 0.780 |
Why?
| | beta Catenin | 2 | 2024 | 253 | 0.780 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 311 | 0.760 |
Why?
| | Circulating Tumor DNA | 2 | 2024 | 34 | 0.750 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 1058 | 0.740 |
Why?
| | Reperfusion Injury | 1 | 2024 | 279 | 0.710 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 82 | 0.700 |
Why?
| | Osteosarcoma | 5 | 2024 | 74 | 0.700 |
Why?
| | Pituitary Diseases | 1 | 2020 | 20 | 0.700 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 37 | 0.680 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.660 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 224 | 0.590 |
Why?
| | DNA, Neoplasm | 2 | 2023 | 164 | 0.540 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 3 | 2024 | 25 | 0.530 |
Why?
| | RNA-Binding Protein EWS | 3 | 2024 | 26 | 0.530 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4282 | 0.470 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 42 | 0.460 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2024 | 214 | 0.450 |
Why?
| | Neoplastic Cells, Circulating | 3 | 2025 | 80 | 0.440 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1710 | 0.420 |
Why?
| | Thrombocytopenia | 1 | 2015 | 198 | 0.400 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 250 | 0.390 |
Why?
| | Precision Medicine | 1 | 2016 | 426 | 0.380 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 254 | 0.380 |
Why?
| | Hydroxyurea | 1 | 2011 | 35 | 0.370 |
Why?
| | Transfusion Reaction | 1 | 2011 | 46 | 0.360 |
Why?
| | Prognosis | 7 | 2025 | 4013 | 0.360 |
Why?
| | Perioperative Care | 1 | 2011 | 178 | 0.320 |
Why?
| | Sarcoma | 4 | 2024 | 188 | 0.310 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 672 | 0.300 |
Why?
| | Translocation, Genetic | 2 | 2021 | 105 | 0.290 |
Why?
| | Child | 13 | 2025 | 21819 | 0.280 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1059 | 0.280 |
Why?
| | Anemia, Sickle Cell | 1 | 2011 | 269 | 0.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1684 | 0.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1396 | 0.270 |
Why?
| | Albumins | 2 | 2024 | 113 | 0.260 |
Why?
| | Deoxycytidine | 2 | 2024 | 179 | 0.250 |
Why?
| | Paclitaxel | 2 | 2024 | 227 | 0.250 |
Why?
| | Eflornithine | 1 | 2025 | 6 | 0.250 |
Why?
| | Polyamines | 1 | 2025 | 40 | 0.240 |
Why?
| | B7 Antigens | 1 | 2024 | 13 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 868 | 0.220 |
Why?
| | Mice | 7 | 2025 | 17759 | 0.220 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3406 | 0.210 |
Why?
| | Interleukin-8 | 1 | 2024 | 268 | 0.210 |
Why?
| | Adolescent | 9 | 2025 | 21385 | 0.200 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2023 | 41 | 0.200 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.190 |
Why?
| | Fertility Preservation | 1 | 2022 | 49 | 0.190 |
Why?
| | Administration, Inhalation | 1 | 2024 | 683 | 0.190 |
Why?
| | Male | 10 | 2025 | 67330 | 0.180 |
Why?
| | Humans | 22 | 2025 | 136803 | 0.180 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 10 | 0.180 |
Why?
| | Mice, SCID | 3 | 2016 | 366 | 0.180 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 953 | 0.180 |
Why?
| | Rhabdomyosarcoma | 2 | 2020 | 72 | 0.170 |
Why?
| | Mice, Inbred NOD | 3 | 2016 | 600 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 496 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2024 | 778 | 0.160 |
Why?
| | Animals | 7 | 2025 | 36850 | 0.160 |
Why?
| | Female | 11 | 2025 | 72816 | 0.150 |
Why?
| | Neoplasm Metastasis | 2 | 2025 | 657 | 0.150 |
Why?
| | Down-Regulation | 1 | 2021 | 656 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 209 | 0.150 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1772 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 558 | 0.140 |
Why?
| | Cyclophosphamide | 1 | 2017 | 247 | 0.130 |
Why?
| | Calmodulin-Binding Proteins | 1 | 2016 | 13 | 0.130 |
Why?
| | Radiotherapy | 1 | 2017 | 201 | 0.120 |
Why?
| | Bone Marrow Transplantation | 1 | 2017 | 287 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2025 | 2476 | 0.120 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.120 |
Why?
| | Neoplasms | 2 | 2022 | 2643 | 0.120 |
Why?
| | Pyrazines | 1 | 2015 | 90 | 0.110 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 216 | 0.110 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 382 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 319 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 739 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3265 | 0.100 |
Why?
| | Time Factors | 1 | 2024 | 6809 | 0.100 |
Why?
| | Transcription Factors | 1 | 2021 | 1718 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2016 | 423 | 0.100 |
Why?
| | Neoplasm Staging | 1 | 2016 | 1373 | 0.100 |
Why?
| | Glioblastoma | 1 | 2015 | 343 | 0.090 |
Why?
| | Pyridines | 1 | 2015 | 506 | 0.090 |
Why?
| | Flow Cytometry | 1 | 2015 | 1180 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1690 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3947 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 1044 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 1430 | 0.080 |
Why?
| | Child, Preschool | 2 | 2020 | 10997 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2020 | 2234 | 0.070 |
Why?
| | Young Adult | 5 | 2024 | 13129 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1235 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2024 | 14 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1733 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2017 | 10748 | 0.050 |
Why?
| | Infant | 1 | 2015 | 9395 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 321 | 0.040 |
Why?
| | Adult | 5 | 2024 | 37643 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 288 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2023 | 15510 | 0.040 |
Why?
| | HLA Antigens | 1 | 2021 | 237 | 0.040 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 202 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 388 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 209 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 217 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 349 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 340 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2020 | 264 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2020 | 436 | 0.030 |
Why?
| | Transplantation, Haploidentical | 1 | 2017 | 22 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 780 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 575 | 0.030 |
Why?
| | Biological Evolution | 1 | 2020 | 467 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1993 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2016 | 184 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2016 | 133 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 138 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 534 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1231 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 975 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1544 | 0.030 |
Why?
| | Prospective Studies | 1 | 2024 | 7573 | 0.020 |
Why?
| | Cell Survival | 1 | 2015 | 1116 | 0.020 |
Why?
| | Patient Care Team | 1 | 2017 | 626 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5106 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2016 | 801 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1572 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7593 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3009 | 0.020 |
Why?
| | Apoptosis | 1 | 2016 | 2552 | 0.020 |
Why?
| | Aged | 1 | 2021 | 23808 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 33239 | 0.010 |
Why?
|
|
Hayashi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|